Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$21.15
-3.5%
$20.76
$17.45
$70.07
$838.82M0.19895,108 shs472,599 shs
Azenta, Inc. stock logo
AZTA
Azenta
$29.13
-1.7%
$27.56
$23.91
$63.58
$1.36B1.62700,670 shs571,485 shs
CONMED Corporation stock logo
CNMD
CONMED
$51.72
-0.9%
$54.86
$46.00
$78.19
$1.61B1.24442,171 shs350,829 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$9.23
+0.3%
$8.37
$5.90
$28.18
$952.96M2.152.91 million shs3.94 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
0.00%+1.79%+5.56%-10.72%-58.60%
Azenta, Inc. stock logo
AZTA
Azenta
0.00%-3.14%+9.78%-22.47%-47.70%
CONMED Corporation stock logo
CNMD
CONMED
0.00%-2.49%-5.74%-14.23%-22.21%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
0.00%+10.71%+0.44%-1.18%-62.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
4.2521 of 5 stars
3.12.00.04.32.41.71.9
Azenta, Inc. stock logo
AZTA
Azenta
3.2396 of 5 stars
3.31.00.00.02.62.52.5
CONMED Corporation stock logo
CNMD
CONMED
4.4634 of 5 stars
2.12.02.54.32.80.83.1
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.4419 of 5 stars
4.31.00.04.72.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2.25
Hold$32.0851.70% Upside
Azenta, Inc. stock logo
AZTA
Azenta
2.50
Moderate Buy$50.6773.93% Upside
CONMED Corporation stock logo
CNMD
CONMED
2.20
Hold$62.2020.26% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.67
Moderate Buy$34.95278.66% Upside

Current Analyst Ratings Breakdown

Latest AMN, CNMD, NTLA, and AZTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/12/2025
CONMED Corporation stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$61.00
6/3/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $54.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00 ➝ $7.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/20/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/19/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/13/2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $25.50
5/12/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $45.00
5/9/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$2.98B0.27$13.22 per share1.60$18.56 per share1.14
Azenta, Inc. stock logo
AZTA
Azenta
$656.32M2.03$4.47 per share6.52$36.16 per share0.81
CONMED Corporation stock logo
CNMD
CONMED
$1.31B1.22$6.66 per share7.77$31.16 per share1.66
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M16.52N/AN/A$8.56 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
-$146.98M-$4.33N/A8.74N/A-5.80%13.39%4.17%8/6/2025 (Estimated)
Azenta, Inc. stock logo
AZTA
Azenta
-$164.17M-$1.39N/A31.66N/A-10.31%1.30%1.10%8/5/2025 (Estimated)
CONMED Corporation stock logo
CNMD
CONMED
$132.42M$3.8013.6110.201.349.02%14.36%5.86%7/30/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)

Latest AMN, CNMD, NTLA, and AZTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$0.19$0.45+$0.26-$0.03$670.08 million$689.53 million
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
5/7/2025Q2 2025
Azenta, Inc. stock logo
AZTA
Azenta
$0.09$0.05-$0.04-$0.89$140.87 millionN/A
4/30/2025Q1 2025
CONMED Corporation stock logo
CNMD
CONMED
$0.81$0.95+$0.14$0.19$313.38 million$321.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
N/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
N/AN/AN/AN/AN/A
CONMED Corporation stock logo
CNMD
CONMED
$0.801.55%N/A21.05%N/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A

Latest AMN, CNMD, NTLA, and AZTA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/21/2025
CONMED Corporation stock logo
CNMD
CONMED
quarterly$0.201.34%6/13/20256/13/20257/3/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
1.39
1.08
1.08
Azenta, Inc. stock logo
AZTA
Azenta
N/A
3.22
2.84
CONMED Corporation stock logo
CNMD
CONMED
0.91
2.26
1.00
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
4.90
4.90

Institutional Ownership

CompanyInstitutional Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
99.23%
Azenta, Inc. stock logo
AZTA
Azenta
99.08%
CONMED Corporation stock logo
CNMD
CONMED
N/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%

Insider Ownership

CompanyInsider Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
0.93%
Azenta, Inc. stock logo
AZTA
Azenta
10.62%
CONMED Corporation stock logo
CNMD
CONMED
3.10%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2,96838.28 million37.93 millionOptionable
Azenta, Inc. stock logo
AZTA
Azenta
3,30045.78 million40.92 millionOptionable
CONMED Corporation stock logo
CNMD
CONMED
3,90030.94 million29.98 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million100.37 millionOptionable

Recent News About These Companies

Intellia Therapeutics, Inc. stock logo
Brokers Issue Forecasts for NTLA FY2026 Earnings
Intellia Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN Healthcare Services stock logo

AMN Healthcare Services NYSE:AMN

$21.15 -0.76 (-3.47%)
Closing price 03:59 PM Eastern
Extended Trading
$20.96 -0.19 (-0.92%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Azenta stock logo

Azenta NASDAQ:AZTA

$29.13 -0.51 (-1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$29.10 -0.02 (-0.09%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

CONMED stock logo

CONMED NYSE:CNMD

$51.72 -0.47 (-0.90%)
Closing price 03:59 PM Eastern
Extended Trading
$51.66 -0.05 (-0.11%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$9.23 +0.03 (+0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$9.35 +0.12 (+1.29%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.